Pipeline

We are working to deliver best-in-class pan-variant TKIs to fight cancer.

Our pipeline focuses on developing next-generation TKIs that address the key limitation of drug resistance.
Program/Target
Indication Stage
Discovery
IND-Enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
THE-630/KIT GIST
GIST Phase 1
4th-generation EGFR NSCLC
NSCLC Discovery
3rd Kinase Target Undisclosed
Undisclosed Discovery
We are targeting cancers driven by clinically validated driver oncogenes, where current therapies are limited by the development of resistance.

LEARN ABOUT OUR DISEASE FOCUS